Key result
Mitral valve replacement in patients with severe pulmonary hypertension was safe, with 0% mortality at 3 months and significant improvements in mean pulmonary artery pressure.
Why the study?
Does conventional surgical MVR improve early hemodynamic outcomes safely in patients with rheumatic mitral stenosis and severe pulmonary hypertension compared to those with mild pulmonary hypertension?
Observational (n=40)
Yes
Does conventional surgical MVR improve early hemodynamic outcomes safely in patients with rheumatic mitral stenosis and severe pulmonary hypertension compared to those with mild pulmonary hypertension?
Conventional surgical mitral valve replacement is safe and effective in improving hemodynamics in patients with rheumatic mitral stenosis, even in the presence of severe pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
May support MVR safety in severe PH; leaves open need for RCTs versus milder cases.
ObjectivesTo evaluate and compare the early hemodynamic results and echocardiographic data after rheumatic mitral valve replacement (MVR) in patients with mild and severe pulmonary hypertension (PH).BackgroundDevelopment of PH in association with valvular dysfunction is a marker of advanced disease. Some authors have reported no greater risk in patients with severe PH compared with those with a mild degree of PH, whereas others reported that severe PH is associated with a greater operative risk and a poorer long-term prognosis. It is desirable to reassess the outcome in these patients with newer anesthetic agents, improved valve prostheses, myocardial protection, and postoperative care.Patients and methodsBetween September 2013 and May 2015, this multicenter prospective observational study included 40 patients who presented with rheumatic mitral stenosis indicated for elective MVR divided into two equal groups: group A, with a mean pulmonary artery pressure (mPAP) equal to 26-40 mmHg, and group B, with mPAP more than 55 mmHg. All patients underwent conventional surgical MVR using cardiopulmonary bypass. Early hemodynamic improvement was observed with follow-up transthoracic echo performed 1 week and 3 months postoperativelyResultsOur study included 17 male and 23 female patients with a mean age of 32.40 years; all of them underwent conventional MVR with cardiopulmonary bypass. Throughout our study, we detected a statistically significant difference between both groups regarding the duration of postoperative mechanical ventilation and improvement in mPAP in both groups. There was a single case of morbidity in group B with no cases of mortality for 3 months postoperatively in both groups.ConclusionMVR is safe and effective even in patients with severe PH.
No takes yet. Share an insight, caveat, or question.
Abdellatif et al. (2016) conducted an observational in Rheumatic mitral stenosis with pulmonary hypertension (n=40). Severe pulmonary hypertension (mPAP > 55 mmHg) vs. Mild pulmonary hypertension (mPAP 26-40 mmHg) was evaluated on Duration of postoperative mechanical ventilation and improvement in mean pulmonary artery pressure. Mitral valve replacement in patients with severe pulmonary hypertension was safe, with 0% mortality at 3 months and significant improvements in mean pulmonary artery pressure.
Synapse has enriched 10 related papers. Consider them for comparative context: